Predictions

Gilead Sciences Q2 2026 Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) net sales are >=3.7 billion USD

Q1 Biktarvy $3.4B. Consensus $3.6B. Gap bracket between >=3.6B (p=0.40) and >=3.9B (p=0.28). Requires +8.8% sequential growth from Q1. Gilead HIV franchise growing steadily; Biktarvy is dominant HIV SOC. Gilead serial non-GAAP beater (Q1 beat 26%). BIC/LEN PDUFA Aug 27 — any competitive cannibalization of Biktarvy by BIC/LEN is not Q2 revenue impact. P(>=3.7B) = 0.35 interpolated. Calibration: pharma beat base rate 70-75% for Gilead HIV franchise applied.

Gilead Sciences Q2 2026 Yeztugo (lenacapavir PrEP, injectable) net sales are >=250 million USD

Gap bracket between >=200M (p=0.55) and >=300M (p=0.30). FY 2026 guidance raised to ~$1B implying ~$250M/Q average pace. Q2 is second full commercial quarter for lenacapavir as PrEP. CDC endorsement drives insurance coverage expansion; MSM and trans women populations showing strong uptake. Cornelius: launch-phase conservatism does not apply here (Q2 is multiple quarters post-launch). P=0.40 interpolated midpoint.

Pfizer Q2 2026 non-GAAP adjusted diluted EPS is >=0.80 USD

Consensus $0.68. Gap bracket between >=0.75 (p=0.40) and >=0.85 (p=0.22). Pfizer is in post-COVID reset and Seagen integration. Cornelius: Pfizer is NOT a momentum pharma — apply Biogen-style logic, 40-50% revenue beat probability but cost-cutting may boost EPS. $0.80 requires 17.6% beat vs consensus. Paxlovid near-collapse (-62% YoY Q1), Vyndaqel/Padcev/Elrexfio growing. Calibration: restructuring-phase company; near-threshold conservatism applies. P=0.30.

Pfizer Q2 2026 Padcev (enfortumab vedotin-ejfv) global net sales are >=650 million USD

Gap bracket between existing >=600M (p=0.58) and >=700M (p=0.35). Padcev perioperative MIBC label was expanded (PDUFA approved July 10, 2026 per story notes) — new earlier-stage bladder cancer indication creates label expansion demand in Q2. Consensus ~$620-640M. $650M requires ~1.6% above top of consensus range. Pfizer in restructuring but Padcev is an ADC growth asset (Seagen acquisition rationale). Calibration: launch-expanded label creates one-quarter lag for full formulary uptake. P=0.42.

Novo Nordisk H1 2026 Ozempic SC (injectable semaglutide) revenue will be at or above DKK 38B

Q1 2026 Ozempic SC fell -8% YoY but beat estimates. H1 >=DKK 38B requires Q2 Ozempic SC ~flat with Q1. Headwinds from T2D competition, oral Wegovy cannibalization, EUR/USD FX (Cornelius: Q2 typically 85-95% of Q1 EUR figure). Gap bracket above existing >=DKK 36B (p=0.52). NVO FY guidance -4% to -12% CER creates ceiling effect.

Eli Lilly Q2 2026 Mounjaro and Zepbound combined net revenue exceeds $17.0B

Q1 combined Mounjaro+Zepbound = $12.9B. To reach $17B in Q2 requires +32% sequential growth — very aggressive. LLY stock soared on Q2 but $17B would require outsized jump. Existing pred >=16.5B at p=0.40 from gen-31. Medicare Part D $50/month started July 1 which is Q3 tailwind, not Q2. Q2 growth driven by supply normalization and continued formulary wins. P=0.30 given high bar above existing bracket.

Eli Lilly Q2 2026 total revenue is at least $22.5 billion

LLY Q1 was $19.8B. Q2 analyst consensus ~$20.5-21.0B. "Stock soared on Q2" signal from Endpoints News suggests beat. Mounjaro+Zepbound projected >$13B by analysts (up from $12.82B combined Q1). Gap bracket above existing ≥$22.0B (p=0.62) — requires >$2B above consensus. Structural LLY upside: OUS Mounjaro Goldman $9.4B vs $4.5B consensus. P(≥$22.5B) = 0.35 reflecting meaningful but not certain upside.

Eli Lilly Q2 2026 Foundayo (oral orforglipron) US net revenue is at least $120 million

Foundayo launched with ~20K TRx/week (June 26 IQVIA), -4%/wk sequential trend before Medicare Part D July 1. Q2 revenue estimate: ~17-20K avg TRx/week × ~$140/script × 13 weeks ≈ $100-120M. Medicare Part D $50/month started July 1 (Q3 not Q2 tailwind). Gap bracket between ≥$100M (p=0.38) and ≥$150M. p=0.30 reflects upper-end of Q2 range without Medicare tailwind.

Novo Nordisk H1 2026 Wegovy (injectable semaglutide) net sales are at least DKK 39 billion

NVO Q1 2026 Wegovy injectable: DKK 18.2B (+12% YoY). For H1 ≥DKK 39B, Q2 must deliver ≥DKK 20.8B — a +14% sequential step-up. Injectable Wegovy faces supply normalization and competition from oral form, but US market share stable. Aggressive bracket above existing ≥DKK 38B (p=0.28). P(Q2 injectable sequential growth ≥14%) = 0.25, discount for FX/seasonality = 0.22.

Novo Nordisk raises or narrows upward its FY 2026 guidance (adjusted sales and operating profit) on H1 2026 earnings call

NVO guided FY 2026 adjusted sales -4% to -12% CER (revised from -5% to -13%). Oral Wegovy beat in Q1, Q2 should show strong Medicare Part D lead-up demand. However, NVO under investor pressure from CagriSema/Zepbound competitive dynamics. P(guidance raise | strong Q2 oral sema ramp) = 0.55; discounted for Ozempic structural headwinds and cautious management guidance style = 0.45.

Merck Q2 2026: Keytruda (pembrolizumab) + Keytruda SC (Qlex) combined revenue > $9.5B

Keytruda Q1 2026 = $8.03B (+12% YoY). Qlex (Keytruda SC) Q1 = $128M. Combined Q1 = $8.16B. Existing predictions: >$8.5B (p=0.60) and >$9.0B (p=0.55). For >$9.5B: need Q2 growth to ~$9.5B. Q2 2025 Keytruda was ~$8.5B; at 12% YoY Q2 2026 Keytruda = $9.52B; plus Qlex $200M = $9.72B — would exceed. But Cornelius pre-LOE cap for Keytruda (entering pre-LOE awareness window) = cap serial beat at 40-50%. +11pp calibration (raw 0.45). Merck reports Aug 4.

Incyte Jakafi (ruxolitinib) Q2 2026 net product revenues will be at least $900 million when reported around August 6, 2026

Jakafi is Incyte's dominant revenue driver in myelofibrosis and polycythemia vera. Q1 2025 Jakafi ~$770M; at 15% YoY growth = Q1 2026 ~$885M. Q2 typically sequential flat-to-slight-increase. >=900M requires modest growth above Q1. Opzelura (ruxolitinib cream) adds to total but this prediction is Jakafi-specific. Competition from imetelstat for PV/MF niche creates some share concern. Cornelius: rare disease Q2 flat rule applies; prior pred (pred_20260711_053) was >=850M at P=0.59, higher threshol

Merck Q2 2026: Winrevair (sotatercept) revenue > $600M

Winrevair Q1 2026 was $525M (+12% sequential, +88% YoY), beating estimates of $487M. >$600M requires +14% sequential growth from Q1 — aggressive but possible with international expansion (EU, Japan) and continued US uptake growth. Another agent predicted >$550M at p=0.72; this higher threshold of >$600M carries more uncertainty. If Q2 trend is $525M*(1+0.14) = $598M, borderline miss. +11pp calibration (raw 0.45). Merck reports Aug 4.

Incyte reports Q2 2026 Jakafi (ruxolitinib) revenue >= $900M by August 6, 2026

Jakafi Q1 2026 was ~$850M+ with FY guidance of $2.7-2.8B (~$675-700M/Q minimum pace, but tracking ahead). $900M requires modest ~6% QoQ growth; Jakafi has shown consistent sequential gains in MF/PV/GVHD. Biosimilar tofacitinib risk is irrelevant (different indication). Opzelura growth supplements but not included here. Calibration +11pp applied to base ~40%.

Incyte Zynyz (retifanlimab) Q2 2026 net revenues will be >= $100M when reported on or before August 6, 2026

Zynyz (PD-1 inhibitor) approved for MSI-H endometrial cancer (2023) and Merkel cell carcinoma (2024). Commercial trajectory growing from ~$70-80M/Q range. Q2 2026 estimate ~$90-110M; at $100M = meaningful milestone crossing. Calibration +11pp applied to raw 0.40. Novel prediction not previously made.

FDA approves Moderna mFLUSIVA (mRNA-1010) for adults 50-64 ONLY in initial action by August 7 2026, deferring or issuing CRL for the 65+ indication in the same action

VRBPAC voted 9:0 recommending approval for both 50-64 (standard) and 65+ (accelerated approval) in June 2026. Historically FDA follows VRBPAC at ~80% for each age group. However Moderna had an RTF reversed February 2026 indicating residual FDA skepticism specifically about 65+ relative VE data (26.6% vs standard shot). Base probability of split-action (50-64 approved, 65+ deferred) is low given unanimous committee, but RTF history and modest 65+ VE raise the tail risk. Calibration: raised slight

Rhythm Biosciences reports Q2 2026 setmelanotide total revenue >= $55M by August 6, 2026

Setmelanotide is the approved therapy for POMC, PCSK1, and LEPR deficiency obesity; prior prediction at $48M had 68% probability (before +11pp correction implies underlying ~57%). $55M is ~15% above that threshold, requiring continued rare disease uptake and possible new indication contributions. Imcivree label expansion to Bardet-Biedl Syndrome and ALMS adds incremental patients. Calibration +11pp applied to base ~38%.

A pharma or biotech M&A acquisition deal valued at more than $5 billion is announced in the two-week period ending August 6, 2026.

Cornelius base rate: 35-40% per 7-week window for $5B+ deal; summer calendar June 15-Aug 15 = -5pp. H1 2026 saw $134B in M&A (37 deals >$1B) but post-cluster pipeline depletion is a real risk after Vertex/Crinetics $10B (July 6). Scaling the 7-week base rate to a 2-week window (~15-18%) and applying summer discount and depletion correction yields ~28-32%. Distinct from the remote-added "M&A >$3B by Aug 31" prediction — higher threshold ($5B) and shorter window (Aug 6 vs Aug 31).

Novo Nordisk H1 2026 adjusted sales revenue will exceed DKK 135 billion

Q1 2026 adjusted sales were DKK 70.1B (-4% CER). For H1 to exceed DKK 135B, Q2 adjusted sales need to be at least DKK 64.9B (a decline from Q1 but consistent with the -4% to -12% CER guidance range at the favorable end). Oral Wegovy (launched Jan 2026) is adding revenue while Ozempic faces some pricing pressure from MFN agreement and competitive dynamics. Guidance wide range reflects uncertainty but DKK 135B is achievable within the favorable part of guidance. Base 60%, calibration raises to 0.7

Novo Nordisk H1 2026 total net sales exceed DKK 145B

Q1 adjusted net sales DKK 70.1B. For H1 >DKK 145B, Q2 needs >DKK 74.9B (+7% vs Q1). Oral Wegovy doubled estimates in Q1 (DKK 2.26B vs DKK 1.16B expected). Continued ramp plus potential early international launch. However company guided -4% to -12% CER for full year. Story already predicts H1 >DKK 140B at 0.50; this higher threshold (DKK 145B) is more uncertain. ~35% gut calibrated +11pp.